Real-World Experience With Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma

Following its FDA approval in 2020 based on results from the ZUMA-2 trial, brexucabtagene autoleucel (brexu-cel) has been implemented into standard care for patients with relapsed/refractory mantle cell lymphoma (MCL). In a subsequent study evaluating data on the use of brexu-cel in real-world practice, researchers judged the treatment to have “encouraging” safety and efficacy profiles … Continue reading Real-World Experience With Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma